INIFY Laboratories AB
OSE:INIFY
INIFY Laboratories AB
INIFY Laboratories AB engages in the provision of cancer diagnostics through laboratory services within pathology. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2022-06-20. The firm uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The firm origins from ContextVision.
INIFY Laboratories AB engages in the provision of cancer diagnostics through laboratory services within pathology. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2022-06-20. The firm uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The firm origins from ContextVision.
